The erythroid marrow and circulating red blood cells (RBCs) are the key components of the
human erythron. Abnormalities of the erythron that are responsible for anemia can be …

Luspatercept (Reblozyl) was recently approved for treating patients with transfusion-
dependent lower-risk myelodysplastic syndrome (MDS) with ring sideroblasts (RS) and/or …

Introduction: MDS is associated with an erythroid maturation defect, characterized by
ineffective erythropoiesis leading to anemia and RBC transfusion dependence. Treatment of …

After years of reliance on transfusion alone to address anemia and suppress ineffective
erythropoiesis in β-thalassemia, many new therapies are now in development. Luspatercept …

Iron and erythropoiesis are inextricably linked. Erythropoiesis is a dynamic process that
requires 30–40mg of iron per day. In normal circumstances this is met from red cell …

Erythropoiesis describes the hematopoietic process of cell proliferation and differentiation
that results in the production of mature circulating erythrocytes. Adult humans produce 200 …

The relationships between erythropoietin (EPO), iron, and erythropoiesis and the presence
of iron‐restricted erythropoiesis have important implications in anemia management. Iron …

Background Patients with anemia and lower-risk myelodysplastic syndromes in whom
erythropoiesis-stimulating agent therapy is not effective generally become dependent on red …

We present herein an approach to diagnosing the cause of chronic anemia based on a
patient's history and complete blood cell count (CBC). Four patterns that are encountered …

Luspatercept, a ligand‐trapping fusion protein, binds select TGF‐β superfamily ligands
implicated in thalassemic erythropoiesis, promoting late‐stage erythroid maturation …